Last reviewed · How we verify
Jennifer Gassman, PhD — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Lower Dose Sodium Bicarbonate | Lower Dose Sodium Bicarbonate | phase 3 | Alkalizing agent | Nephrology | ||
| Higher Dose Sodium Bicarbonate | Higher Dose Sodium Bicarbonate | phase 3 | Alkalinizing agent | Nephrology |
Therapeutic area mix
- Nephrology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hospital General "Dr. Miguel Silva" de Morelia · 1 shared drug class
- Nantes University Hospital · 1 shared drug class
- Sheba Medical Center · 1 shared drug class
- The Western Pennsylvania Hospital · 1 shared drug class
- University of Baghdad · 1 shared drug class
- VA Greater Los Angeles Healthcare System · 1 shared drug class
- VA Office of Research and Development · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jennifer Gassman, PhD:
- Jennifer Gassman, PhD pipeline updates — RSS
- Jennifer Gassman, PhD pipeline updates — Atom
- Jennifer Gassman, PhD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jennifer Gassman, PhD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jennifer-gassman-phd. Accessed 2026-05-17.